Review



tgf β1  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 96

    Structured Review

    R&D Systems tgf β1
    Tgf β1, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 438 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+tgf+%CE%B21/Human+TGF-beta+1+DuoSet+ELISA/pm42998492-212-5-2
    Average 96 stars, based on 438 article reviews
    tgf β1 - by Bioz Stars, 2026-11
    96/100 stars

    Images

    Related Articles

    Activation Assay:

    Article Title: Botulinum Neurotoxin Type A1 Alleviates Bleomycin-induced Skin Fibrosis by Inhibiting PI3K-Akt Pathway and Associated Cell Cycle and Proliferation.
    Article Snippet: This is a PDF of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability.. This version will undergo additional copyediting, typesetting and review before it is published in its final form.. As such, this version is no longer the Accepted Manuscript, but it is not yet the definitive Version of Record; we are providing this early version to give early visibility of the article.

    Article Title: Yizong Tongluo formula attenuates idiopathic pulmonary fibrosis and inflammatory injury by inhibiting HIF-1α/LSH/SCD1-mediated ferroptosis
    Article Snippet: .. To establish an in vitro model of IPF, fibrotic activation was induced by treating the MRC-5 cells with 5 ng/mL of recombinant human TGF-β1 (R&D Systems) for a duration of 48 hours ( ) experimental groups were designated as follows: Normal control (NC, untreated MRC-5 cells), Model (TGF-β1-induced cells), si-NC (siRNA negative control), siHIF-1α (Model + 50 nM HIF-1α-targeting siRNA), YZTLF (Model + 200 mg/L YZTLF), and Combination (Model + YZTLF + si-HIF-1α). ..

    Recombinant:

    Article Title: Botulinum Neurotoxin Type A1 Alleviates Bleomycin-induced Skin Fibrosis by Inhibiting PI3K-Akt Pathway and Associated Cell Cycle and Proliferation.
    Article Snippet: This is a PDF of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability.. This version will undergo additional copyediting, typesetting and review before it is published in its final form.. As such, this version is no longer the Accepted Manuscript, but it is not yet the definitive Version of Record; we are providing this early version to give early visibility of the article.

    Article Title: Engineering Bi-Specific CAR-NK Cells to Restore Antibody-Dependent Cellular Cytotoxicity in Solid Tumors
    Article Snippet: .. For TGF-β suppression assays, PBNK cells were treated with recombinant human TGF-β1 (10 ng/mL; R&D Systems, Minneapolis, MN, USA) for defined time points (1 h, 24 h, 72 h, or 144 h) to assess temporal changes in phenotype and function. .. All cell lines were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA).

    Article Title: Yizong Tongluo formula attenuates idiopathic pulmonary fibrosis and inflammatory injury by inhibiting HIF-1α/LSH/SCD1-mediated ferroptosis
    Article Snippet: .. To establish an in vitro model of IPF, fibrotic activation was induced by treating the MRC-5 cells with 5 ng/mL of recombinant human TGF-β1 (R&D Systems) for a duration of 48 hours ( ) experimental groups were designated as follows: Normal control (NC, untreated MRC-5 cells), Model (TGF-β1-induced cells), si-NC (siRNA negative control), siHIF-1α (Model + 50 nM HIF-1α-targeting siRNA), YZTLF (Model + 200 mg/L YZTLF), and Combination (Model + YZTLF + si-HIF-1α). ..

    Article Title: Runx2 Regulated Airway Homeostasis Is Disrupted in Asthma
    Article Snippet: .. Nonasthmatic (NA) and asthmatic (A) ASM cells were seeded in six- well plates (104 cells/cm2), in 5% (v/v) FBS/DMEM and grown for 3 days before quiescing for 24 or 72 h in 0.1% (w/v) BSA/DMEM followed by stimulation with recombinant human TGF- β1 (1 ng/mL, R&D Systems, Minneapolis, USA). .. Human TERT- immortalized A- ASM cell lines (iA- ASM) [28] were transfected with ORF constructs (2 μg/106 cells) for RUNX2 isoforms ([V1: Genescript (Piscataway, NJ)] [V1L, V2: BIOMATIC (Wilmington, DE)]) using the Amaxa Basic Nucleofector Kit (VPI- 1004, Lonza).

    Article Title: Runx2 Regulated Airway Homeostasis Is Disrupted in Asthma
    Article Snippet: .. Nonasthmatic (NA) and asthmatic (A) ASM cells were seeded in six‐well plates (10 4 cells/cm 2 ), in 5% (v/v) FBS/DMEM and grown for 3 days before quiescing for 24 or 72 h in 0.1% (w/v) BSA/DMEM followed by stimulation with recombinant human TGF‐β1 (1 ng/mL, R&D Systems, Minneapolis, USA). .. Human TERT‐immortalized A‐ASM cell lines (iA‐ASM) [ ] were transfected with ORF constructs (2 μg/10 6 cells) for RUNX2 isoforms ([V1: Genescript (Piscataway, NJ)] [V1 l , V2: BIOMATIC (Wilmington, DE)]) using the Amaxa Basic Nucleofector Kit (VPI‐1004, Lonza).

    Article Title: Engineering Bi-Specific CAR-NK Cells to Restore Antibody-Dependent Cellular Cytotoxicity in Solid Tumors.
    Article Snippet: .. For TGF-β suppression assays, PBNK cells were treated with recombinant human TGF-β1 (10 ng/mL; R&D Systems, Minneapolis, MN, USA) for defined time points (1 h, 24 h, 72 h, or 144 h) to assess temporal changes in phenotype and function. .. All cell lines were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA).

    Inhibition:

    Article Title: Botulinum Neurotoxin Type A1 Alleviates Bleomycin-induced Skin Fibrosis by Inhibiting PI3K-Akt Pathway and Associated Cell Cycle and Proliferation.
    Article Snippet: This is a PDF of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability.. This version will undergo additional copyediting, typesetting and review before it is published in its final form.. As such, this version is no longer the Accepted Manuscript, but it is not yet the definitive Version of Record; we are providing this early version to give early visibility of the article.

    Solvent:

    Article Title: Botulinum Neurotoxin Type A1 Alleviates Bleomycin-induced Skin Fibrosis by Inhibiting PI3K-Akt Pathway and Associated Cell Cycle and Proliferation.
    Article Snippet: This is a PDF of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability.. This version will undergo additional copyediting, typesetting and review before it is published in its final form.. As such, this version is no longer the Accepted Manuscript, but it is not yet the definitive Version of Record; we are providing this early version to give early visibility of the article.

    In Vitro:

    Article Title: Yizong Tongluo formula attenuates idiopathic pulmonary fibrosis and inflammatory injury by inhibiting HIF-1α/LSH/SCD1-mediated ferroptosis
    Article Snippet: .. To establish an in vitro model of IPF, fibrotic activation was induced by treating the MRC-5 cells with 5 ng/mL of recombinant human TGF-β1 (R&D Systems) for a duration of 48 hours ( ) experimental groups were designated as follows: Normal control (NC, untreated MRC-5 cells), Model (TGF-β1-induced cells), si-NC (siRNA negative control), siHIF-1α (Model + 50 nM HIF-1α-targeting siRNA), YZTLF (Model + 200 mg/L YZTLF), and Combination (Model + YZTLF + si-HIF-1α). ..

    Control:

    Article Title: Yizong Tongluo formula attenuates idiopathic pulmonary fibrosis and inflammatory injury by inhibiting HIF-1α/LSH/SCD1-mediated ferroptosis
    Article Snippet: .. To establish an in vitro model of IPF, fibrotic activation was induced by treating the MRC-5 cells with 5 ng/mL of recombinant human TGF-β1 (R&D Systems) for a duration of 48 hours ( ) experimental groups were designated as follows: Normal control (NC, untreated MRC-5 cells), Model (TGF-β1-induced cells), si-NC (siRNA negative control), siHIF-1α (Model + 50 nM HIF-1α-targeting siRNA), YZTLF (Model + 200 mg/L YZTLF), and Combination (Model + YZTLF + si-HIF-1α). ..

    Negative Control:

    Article Title: Yizong Tongluo formula attenuates idiopathic pulmonary fibrosis and inflammatory injury by inhibiting HIF-1α/LSH/SCD1-mediated ferroptosis
    Article Snippet: .. To establish an in vitro model of IPF, fibrotic activation was induced by treating the MRC-5 cells with 5 ng/mL of recombinant human TGF-β1 (R&D Systems) for a duration of 48 hours ( ) experimental groups were designated as follows: Normal control (NC, untreated MRC-5 cells), Model (TGF-β1-induced cells), si-NC (siRNA negative control), siHIF-1α (Model + 50 nM HIF-1α-targeting siRNA), YZTLF (Model + 200 mg/L YZTLF), and Combination (Model + YZTLF + si-HIF-1α). ..

    Enzyme-linked Immunosorbent Assay:

    Article Title: Mesenchymal stem cells derived from human bone marrow ameliorate monosodium urate crystal-induced inflammation.
    Article Snippet: Mesenchymal stem cells (MSCs) have anti-inflammatory properties and have been implicated in several inflammatory diseases.. Acute gout is initiated by IL-1β produced by monosodium urate crystal (MSU)-stimulated macrophages via activation of NLRP3 inflammasomes.. We sought to investigate whether MSCs derived from human bone marrow (hBM-MSCs) suppress MSU-induced inflammation. hBM-MSCs were stimulated with proinflammatory cytokine cocktails or co-cultured with MSU-treated macrophages.



    Similar Products

    95
    MedChemExpress recombinant human tgf β1
    Recombinant Human Tgf β1, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+tgf+%CE%B21/TGF+beta+1%2FTGFB1%2C+Human/pm42887830-60-28-32
    Average 95 stars, based on 1 article reviews
    recombinant human tgf β1 - by Bioz Stars, 2026-11
    95/100 stars
      Buy from Supplier

    95
    Sino Biological tgf β1
    Tgf β1, supplied by Sino Biological, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+tgf+%CE%B21/Human+%2F+Rhesus+%2F+Cynomolgus+%2F+Canine+TGF-beta+1+%2F+TGFB1+Protein/pm42580572-147-13-14
    Average 95 stars, based on 1 article reviews
    tgf β1 - by Bioz Stars, 2026-11
    95/100 stars
      Buy from Supplier

    96
    R&D Systems tgf β1
    Tgf β1, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+tgf+%CE%B21/Human+TGF-beta+1+DuoSet+ELISA/pm42998492-212-5-2
    Average 96 stars, based on 1 article reviews
    tgf β1 - by Bioz Stars, 2026-11
    96/100 stars
      Buy from Supplier

    96
    R&D Systems recombinant human tgf β1
    (A) Experimental workflows for ex vivo (upper path: resected human GBM tissue, 24-hour incubation, replating) and in vitro (lower path: macrophage <t>culture,</t> <t>TGF-β1</t> immunosuppressive polarization) sample preparation, followed by single-well pLIFU delivery, immune marker staining, and spectral flow cytometry. (B) The four-transducer microplate adapter used for all in vitro and ex vivo delivery: air-backed transducers in sealed housings, gel-coupled to the underside of a 96-well plate at a 27 mm pitch so that each element addresses every third well; the in vivo configuration, in which a single transducer in the same housing is held in the stereotaxic arm, is shown in and and . (C) FUS platform configured for in vitro delivery, with the plate seated on the adapter. (D) To-scale cross-section of the measured focus in one well of a flat-bottom 96-well plate (well bottom diameter 6.35 mm, pitch 9.0 mm, base 1.27 mm, 100 µL of medium): the orange ellipse is the −6 dB focal zone measured through the plate (2.0 mm wide, 10.9 mm long, peak placed at the cell monolayer or tissue layer; dashed above the medium surface), the red bar the −3 dB width (1.3 mm) and the bracket the −20 dB width (2.8 mm), both in free field; the single-element transducer (13 mm aperture, 10 mm radius of curvature) is gel-coupled beneath the target well. (E) Ex vivo results: pLIFU/control fold-change ratios for CD80, iNOS, CD206, and Arg1 across four pLIFU parameter combinations (0.5 or 1.5 MPa free-field peak negative pressure; 5 or 25 Hz PRF) in resected human GBM tissue (n = 2 patients; bars, mean of the two patients; points, individual patients, each the mean of duplicate wells). (F) Pooled pLIFU effects across all four parameter combinations in patient 1 (fold-change ratios relative to that patient’s untreated wells, with p-values); CX3CR1 and CD163 were measured in the same staining panel as the other markers. (G) Proinflammatory shift ratios (iNOS/Arg1 and iNOS/CD206) across ex vivo pLIFU conditions (bars, mean of the two patients; points, individual patients). (H) RAW 264.7 MHC II expression (% of live cells) across immunosuppressive control, three pLIFU doses (0.5, 1.0, and 1.5 MPa free-field peak negative pressure; MI 0.41, 0.82, and 1.22), and proinflammatory control (n = 5 independent experiments; bars, mean ± SD; points, individual experiments). (I) RAW 264.7 CD80 expression across conditions; brackets give Welch’s t-test p-values versus immunosuppressive control. (J) MHC II within-experiment pLIFU/immunosuppressive ratio by dose (overall ratio 1.65, p = 0.0041, one-sample t-test versus 1.0). (K) CD80 normalized ratio by dose (overall 0.73, p = 0.0008). (L) MHC II dose-response regression of within-experiment ratios on peak negative pressure (R = 0.50, p = 0.059). (M) CD80 dose-response regression (R = −0.07, p = 0.81). (N) THP-1 CD80 expression across conditions (n = 2 independent experiments). (O) THP-1 ARG1 expression across conditions. (P) THP-1 HLA-DR normalized ratio by dose (overall 0.97, p = 0.64). (Q) THP-1 ARG1 normalized ratio by dose (overall 0.52, p = 0.0025). (R) THP-1 CD80 normalized ratio by dose (overall 0.64, p = 0.0006). (S) THP-1 HLA-DR expression across conditions. (T) Heat maps of mean normalized ratios for all markers across doses in RAW 264.7 (left) and THP-1 (right). (U) Forest plot of pLIFU/immunosuppressive ratios (mean and 95% confidence interval, individual ratios overlaid) for all markers in both cell lines, with the combined CD80 ratio across cell lines (diamond; 0.71, p < 0.0001, n = 21). The vertical line at 1.0 indicates no effect; values below 1.0 indicate reduced expression relative to the immunosuppressive baseline. Dashed lines at 1.0 in E, G, J, K, P, Q, and R indicate no change. All pressures are free-field peak negative pressures; measured in-well values are given in .
    Recombinant Human Tgf β1, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+tgf+%CE%B21/Recombinant+Human+TGF-beta+1+(Human+Cell-expressed)+Protein/bio_rxiv__64898__2026__10__23__760846-102-14-17
    Average 96 stars, based on 1 article reviews
    recombinant human tgf β1 - by Bioz Stars, 2026-11
    96/100 stars
      Buy from Supplier

    94
    Proteintech tgf β1
    (A) Experimental workflows for ex vivo (upper path: resected human GBM tissue, 24-hour incubation, replating) and in vitro (lower path: macrophage <t>culture,</t> <t>TGF-β1</t> immunosuppressive polarization) sample preparation, followed by single-well pLIFU delivery, immune marker staining, and spectral flow cytometry. (B) The four-transducer microplate adapter used for all in vitro and ex vivo delivery: air-backed transducers in sealed housings, gel-coupled to the underside of a 96-well plate at a 27 mm pitch so that each element addresses every third well; the in vivo configuration, in which a single transducer in the same housing is held in the stereotaxic arm, is shown in and and . (C) FUS platform configured for in vitro delivery, with the plate seated on the adapter. (D) To-scale cross-section of the measured focus in one well of a flat-bottom 96-well plate (well bottom diameter 6.35 mm, pitch 9.0 mm, base 1.27 mm, 100 µL of medium): the orange ellipse is the −6 dB focal zone measured through the plate (2.0 mm wide, 10.9 mm long, peak placed at the cell monolayer or tissue layer; dashed above the medium surface), the red bar the −3 dB width (1.3 mm) and the bracket the −20 dB width (2.8 mm), both in free field; the single-element transducer (13 mm aperture, 10 mm radius of curvature) is gel-coupled beneath the target well. (E) Ex vivo results: pLIFU/control fold-change ratios for CD80, iNOS, CD206, and Arg1 across four pLIFU parameter combinations (0.5 or 1.5 MPa free-field peak negative pressure; 5 or 25 Hz PRF) in resected human GBM tissue (n = 2 patients; bars, mean of the two patients; points, individual patients, each the mean of duplicate wells). (F) Pooled pLIFU effects across all four parameter combinations in patient 1 (fold-change ratios relative to that patient’s untreated wells, with p-values); CX3CR1 and CD163 were measured in the same staining panel as the other markers. (G) Proinflammatory shift ratios (iNOS/Arg1 and iNOS/CD206) across ex vivo pLIFU conditions (bars, mean of the two patients; points, individual patients). (H) RAW 264.7 MHC II expression (% of live cells) across immunosuppressive control, three pLIFU doses (0.5, 1.0, and 1.5 MPa free-field peak negative pressure; MI 0.41, 0.82, and 1.22), and proinflammatory control (n = 5 independent experiments; bars, mean ± SD; points, individual experiments). (I) RAW 264.7 CD80 expression across conditions; brackets give Welch’s t-test p-values versus immunosuppressive control. (J) MHC II within-experiment pLIFU/immunosuppressive ratio by dose (overall ratio 1.65, p = 0.0041, one-sample t-test versus 1.0). (K) CD80 normalized ratio by dose (overall 0.73, p = 0.0008). (L) MHC II dose-response regression of within-experiment ratios on peak negative pressure (R = 0.50, p = 0.059). (M) CD80 dose-response regression (R = −0.07, p = 0.81). (N) THP-1 CD80 expression across conditions (n = 2 independent experiments). (O) THP-1 ARG1 expression across conditions. (P) THP-1 HLA-DR normalized ratio by dose (overall 0.97, p = 0.64). (Q) THP-1 ARG1 normalized ratio by dose (overall 0.52, p = 0.0025). (R) THP-1 CD80 normalized ratio by dose (overall 0.64, p = 0.0006). (S) THP-1 HLA-DR expression across conditions. (T) Heat maps of mean normalized ratios for all markers across doses in RAW 264.7 (left) and THP-1 (right). (U) Forest plot of pLIFU/immunosuppressive ratios (mean and 95% confidence interval, individual ratios overlaid) for all markers in both cell lines, with the combined CD80 ratio across cell lines (diamond; 0.71, p < 0.0001, n = 21). The vertical line at 1.0 indicates no effect; values below 1.0 indicate reduced expression relative to the immunosuppressive baseline. Dashed lines at 1.0 in E, G, J, K, P, Q, and R indicate no change. All pressures are free-field peak negative pressures; measured in-well values are given in .
    Tgf β1, supplied by Proteintech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+tgf+%CE%B21/Animal-free+Recombinant+Human+TGF+beta+1/10__1016_slash_j__isci__2026__117961-218-2-5
    Average 94 stars, based on 1 article reviews
    tgf β1 - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    97
    R&D Systems recombinant human transforming growth factor beta 1 tgf β1
    (A) Experimental workflows for ex vivo (upper path: resected human GBM tissue, 24-hour incubation, replating) and in vitro (lower path: macrophage <t>culture,</t> <t>TGF-β1</t> immunosuppressive polarization) sample preparation, followed by single-well pLIFU delivery, immune marker staining, and spectral flow cytometry. (B) The four-transducer microplate adapter used for all in vitro and ex vivo delivery: air-backed transducers in sealed housings, gel-coupled to the underside of a 96-well plate at a 27 mm pitch so that each element addresses every third well; the in vivo configuration, in which a single transducer in the same housing is held in the stereotaxic arm, is shown in and and . (C) FUS platform configured for in vitro delivery, with the plate seated on the adapter. (D) To-scale cross-section of the measured focus in one well of a flat-bottom 96-well plate (well bottom diameter 6.35 mm, pitch 9.0 mm, base 1.27 mm, 100 µL of medium): the orange ellipse is the −6 dB focal zone measured through the plate (2.0 mm wide, 10.9 mm long, peak placed at the cell monolayer or tissue layer; dashed above the medium surface), the red bar the −3 dB width (1.3 mm) and the bracket the −20 dB width (2.8 mm), both in free field; the single-element transducer (13 mm aperture, 10 mm radius of curvature) is gel-coupled beneath the target well. (E) Ex vivo results: pLIFU/control fold-change ratios for CD80, iNOS, CD206, and Arg1 across four pLIFU parameter combinations (0.5 or 1.5 MPa free-field peak negative pressure; 5 or 25 Hz PRF) in resected human GBM tissue (n = 2 patients; bars, mean of the two patients; points, individual patients, each the mean of duplicate wells). (F) Pooled pLIFU effects across all four parameter combinations in patient 1 (fold-change ratios relative to that patient’s untreated wells, with p-values); CX3CR1 and CD163 were measured in the same staining panel as the other markers. (G) Proinflammatory shift ratios (iNOS/Arg1 and iNOS/CD206) across ex vivo pLIFU conditions (bars, mean of the two patients; points, individual patients). (H) RAW 264.7 MHC II expression (% of live cells) across immunosuppressive control, three pLIFU doses (0.5, 1.0, and 1.5 MPa free-field peak negative pressure; MI 0.41, 0.82, and 1.22), and proinflammatory control (n = 5 independent experiments; bars, mean ± SD; points, individual experiments). (I) RAW 264.7 CD80 expression across conditions; brackets give Welch’s t-test p-values versus immunosuppressive control. (J) MHC II within-experiment pLIFU/immunosuppressive ratio by dose (overall ratio 1.65, p = 0.0041, one-sample t-test versus 1.0). (K) CD80 normalized ratio by dose (overall 0.73, p = 0.0008). (L) MHC II dose-response regression of within-experiment ratios on peak negative pressure (R = 0.50, p = 0.059). (M) CD80 dose-response regression (R = −0.07, p = 0.81). (N) THP-1 CD80 expression across conditions (n = 2 independent experiments). (O) THP-1 ARG1 expression across conditions. (P) THP-1 HLA-DR normalized ratio by dose (overall 0.97, p = 0.64). (Q) THP-1 ARG1 normalized ratio by dose (overall 0.52, p = 0.0025). (R) THP-1 CD80 normalized ratio by dose (overall 0.64, p = 0.0006). (S) THP-1 HLA-DR expression across conditions. (T) Heat maps of mean normalized ratios for all markers across doses in RAW 264.7 (left) and THP-1 (right). (U) Forest plot of pLIFU/immunosuppressive ratios (mean and 95% confidence interval, individual ratios overlaid) for all markers in both cell lines, with the combined CD80 ratio across cell lines (diamond; 0.71, p < 0.0001, n = 21). The vertical line at 1.0 indicates no effect; values below 1.0 indicate reduced expression relative to the immunosuppressive baseline. Dashed lines at 1.0 in E, G, J, K, P, Q, and R indicate no change. All pressures are free-field peak negative pressures; measured in-well values are given in .
    Recombinant Human Transforming Growth Factor Beta 1 Tgf β1, supplied by R&D Systems, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+tgf+%CE%B21/Recombinant+Human+TGF-beta+1+Protein/10__13052_slash_ijts2246___8765__2026__006-104-3-11
    Average 97 stars, based on 1 article reviews
    recombinant human transforming growth factor beta 1 tgf β1 - by Bioz Stars, 2026-11
    97/100 stars
      Buy from Supplier

    95
    Sino Biological human tgf β1 protein
    (A) Experimental workflows for ex vivo (upper path: resected human GBM tissue, 24-hour incubation, replating) and in vitro (lower path: macrophage <t>culture,</t> <t>TGF-β1</t> immunosuppressive polarization) sample preparation, followed by single-well pLIFU delivery, immune marker staining, and spectral flow cytometry. (B) The four-transducer microplate adapter used for all in vitro and ex vivo delivery: air-backed transducers in sealed housings, gel-coupled to the underside of a 96-well plate at a 27 mm pitch so that each element addresses every third well; the in vivo configuration, in which a single transducer in the same housing is held in the stereotaxic arm, is shown in and and . (C) FUS platform configured for in vitro delivery, with the plate seated on the adapter. (D) To-scale cross-section of the measured focus in one well of a flat-bottom 96-well plate (well bottom diameter 6.35 mm, pitch 9.0 mm, base 1.27 mm, 100 µL of medium): the orange ellipse is the −6 dB focal zone measured through the plate (2.0 mm wide, 10.9 mm long, peak placed at the cell monolayer or tissue layer; dashed above the medium surface), the red bar the −3 dB width (1.3 mm) and the bracket the −20 dB width (2.8 mm), both in free field; the single-element transducer (13 mm aperture, 10 mm radius of curvature) is gel-coupled beneath the target well. (E) Ex vivo results: pLIFU/control fold-change ratios for CD80, iNOS, CD206, and Arg1 across four pLIFU parameter combinations (0.5 or 1.5 MPa free-field peak negative pressure; 5 or 25 Hz PRF) in resected human GBM tissue (n = 2 patients; bars, mean of the two patients; points, individual patients, each the mean of duplicate wells). (F) Pooled pLIFU effects across all four parameter combinations in patient 1 (fold-change ratios relative to that patient’s untreated wells, with p-values); CX3CR1 and CD163 were measured in the same staining panel as the other markers. (G) Proinflammatory shift ratios (iNOS/Arg1 and iNOS/CD206) across ex vivo pLIFU conditions (bars, mean of the two patients; points, individual patients). (H) RAW 264.7 MHC II expression (% of live cells) across immunosuppressive control, three pLIFU doses (0.5, 1.0, and 1.5 MPa free-field peak negative pressure; MI 0.41, 0.82, and 1.22), and proinflammatory control (n = 5 independent experiments; bars, mean ± SD; points, individual experiments). (I) RAW 264.7 CD80 expression across conditions; brackets give Welch’s t-test p-values versus immunosuppressive control. (J) MHC II within-experiment pLIFU/immunosuppressive ratio by dose (overall ratio 1.65, p = 0.0041, one-sample t-test versus 1.0). (K) CD80 normalized ratio by dose (overall 0.73, p = 0.0008). (L) MHC II dose-response regression of within-experiment ratios on peak negative pressure (R = 0.50, p = 0.059). (M) CD80 dose-response regression (R = −0.07, p = 0.81). (N) THP-1 CD80 expression across conditions (n = 2 independent experiments). (O) THP-1 ARG1 expression across conditions. (P) THP-1 HLA-DR normalized ratio by dose (overall 0.97, p = 0.64). (Q) THP-1 ARG1 normalized ratio by dose (overall 0.52, p = 0.0025). (R) THP-1 CD80 normalized ratio by dose (overall 0.64, p = 0.0006). (S) THP-1 HLA-DR expression across conditions. (T) Heat maps of mean normalized ratios for all markers across doses in RAW 264.7 (left) and THP-1 (right). (U) Forest plot of pLIFU/immunosuppressive ratios (mean and 95% confidence interval, individual ratios overlaid) for all markers in both cell lines, with the combined CD80 ratio across cell lines (diamond; 0.71, p < 0.0001, n = 21). The vertical line at 1.0 indicates no effect; values below 1.0 indicate reduced expression relative to the immunosuppressive baseline. Dashed lines at 1.0 in E, G, J, K, P, Q, and R indicate no change. All pressures are free-field peak negative pressures; measured in-well values are given in .
    Human Tgf β1 Protein, supplied by Sino Biological, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+tgf+%CE%B21/Human+%2F+Rhesus+%2F+Cynomolgus+%2F+Canine+TGF-beta+1+%2F+TGFB1+Protein/pm42887381-178-0-3
    Average 95 stars, based on 1 article reviews
    human tgf β1 protein - by Bioz Stars, 2026-11
    95/100 stars
      Buy from Supplier

    Image Search Results


    (A) Experimental workflows for ex vivo (upper path: resected human GBM tissue, 24-hour incubation, replating) and in vitro (lower path: macrophage culture, TGF-β1 immunosuppressive polarization) sample preparation, followed by single-well pLIFU delivery, immune marker staining, and spectral flow cytometry. (B) The four-transducer microplate adapter used for all in vitro and ex vivo delivery: air-backed transducers in sealed housings, gel-coupled to the underside of a 96-well plate at a 27 mm pitch so that each element addresses every third well; the in vivo configuration, in which a single transducer in the same housing is held in the stereotaxic arm, is shown in and and . (C) FUS platform configured for in vitro delivery, with the plate seated on the adapter. (D) To-scale cross-section of the measured focus in one well of a flat-bottom 96-well plate (well bottom diameter 6.35 mm, pitch 9.0 mm, base 1.27 mm, 100 µL of medium): the orange ellipse is the −6 dB focal zone measured through the plate (2.0 mm wide, 10.9 mm long, peak placed at the cell monolayer or tissue layer; dashed above the medium surface), the red bar the −3 dB width (1.3 mm) and the bracket the −20 dB width (2.8 mm), both in free field; the single-element transducer (13 mm aperture, 10 mm radius of curvature) is gel-coupled beneath the target well. (E) Ex vivo results: pLIFU/control fold-change ratios for CD80, iNOS, CD206, and Arg1 across four pLIFU parameter combinations (0.5 or 1.5 MPa free-field peak negative pressure; 5 or 25 Hz PRF) in resected human GBM tissue (n = 2 patients; bars, mean of the two patients; points, individual patients, each the mean of duplicate wells). (F) Pooled pLIFU effects across all four parameter combinations in patient 1 (fold-change ratios relative to that patient’s untreated wells, with p-values); CX3CR1 and CD163 were measured in the same staining panel as the other markers. (G) Proinflammatory shift ratios (iNOS/Arg1 and iNOS/CD206) across ex vivo pLIFU conditions (bars, mean of the two patients; points, individual patients). (H) RAW 264.7 MHC II expression (% of live cells) across immunosuppressive control, three pLIFU doses (0.5, 1.0, and 1.5 MPa free-field peak negative pressure; MI 0.41, 0.82, and 1.22), and proinflammatory control (n = 5 independent experiments; bars, mean ± SD; points, individual experiments). (I) RAW 264.7 CD80 expression across conditions; brackets give Welch’s t-test p-values versus immunosuppressive control. (J) MHC II within-experiment pLIFU/immunosuppressive ratio by dose (overall ratio 1.65, p = 0.0041, one-sample t-test versus 1.0). (K) CD80 normalized ratio by dose (overall 0.73, p = 0.0008). (L) MHC II dose-response regression of within-experiment ratios on peak negative pressure (R = 0.50, p = 0.059). (M) CD80 dose-response regression (R = −0.07, p = 0.81). (N) THP-1 CD80 expression across conditions (n = 2 independent experiments). (O) THP-1 ARG1 expression across conditions. (P) THP-1 HLA-DR normalized ratio by dose (overall 0.97, p = 0.64). (Q) THP-1 ARG1 normalized ratio by dose (overall 0.52, p = 0.0025). (R) THP-1 CD80 normalized ratio by dose (overall 0.64, p = 0.0006). (S) THP-1 HLA-DR expression across conditions. (T) Heat maps of mean normalized ratios for all markers across doses in RAW 264.7 (left) and THP-1 (right). (U) Forest plot of pLIFU/immunosuppressive ratios (mean and 95% confidence interval, individual ratios overlaid) for all markers in both cell lines, with the combined CD80 ratio across cell lines (diamond; 0.71, p < 0.0001, n = 21). The vertical line at 1.0 indicates no effect; values below 1.0 indicate reduced expression relative to the immunosuppressive baseline. Dashed lines at 1.0 in E, G, J, K, P, Q, and R indicate no change. All pressures are free-field peak negative pressures; measured in-well values are given in .

    Journal: bioRxiv

    Article Title: A preclinical platform for focused ultrasound delivery from microplate to awake brain

    doi: 10.64898/2026.10.23.760846

    Figure Lengend Snippet: (A) Experimental workflows for ex vivo (upper path: resected human GBM tissue, 24-hour incubation, replating) and in vitro (lower path: macrophage culture, TGF-β1 immunosuppressive polarization) sample preparation, followed by single-well pLIFU delivery, immune marker staining, and spectral flow cytometry. (B) The four-transducer microplate adapter used for all in vitro and ex vivo delivery: air-backed transducers in sealed housings, gel-coupled to the underside of a 96-well plate at a 27 mm pitch so that each element addresses every third well; the in vivo configuration, in which a single transducer in the same housing is held in the stereotaxic arm, is shown in and and . (C) FUS platform configured for in vitro delivery, with the plate seated on the adapter. (D) To-scale cross-section of the measured focus in one well of a flat-bottom 96-well plate (well bottom diameter 6.35 mm, pitch 9.0 mm, base 1.27 mm, 100 µL of medium): the orange ellipse is the −6 dB focal zone measured through the plate (2.0 mm wide, 10.9 mm long, peak placed at the cell monolayer or tissue layer; dashed above the medium surface), the red bar the −3 dB width (1.3 mm) and the bracket the −20 dB width (2.8 mm), both in free field; the single-element transducer (13 mm aperture, 10 mm radius of curvature) is gel-coupled beneath the target well. (E) Ex vivo results: pLIFU/control fold-change ratios for CD80, iNOS, CD206, and Arg1 across four pLIFU parameter combinations (0.5 or 1.5 MPa free-field peak negative pressure; 5 or 25 Hz PRF) in resected human GBM tissue (n = 2 patients; bars, mean of the two patients; points, individual patients, each the mean of duplicate wells). (F) Pooled pLIFU effects across all four parameter combinations in patient 1 (fold-change ratios relative to that patient’s untreated wells, with p-values); CX3CR1 and CD163 were measured in the same staining panel as the other markers. (G) Proinflammatory shift ratios (iNOS/Arg1 and iNOS/CD206) across ex vivo pLIFU conditions (bars, mean of the two patients; points, individual patients). (H) RAW 264.7 MHC II expression (% of live cells) across immunosuppressive control, three pLIFU doses (0.5, 1.0, and 1.5 MPa free-field peak negative pressure; MI 0.41, 0.82, and 1.22), and proinflammatory control (n = 5 independent experiments; bars, mean ± SD; points, individual experiments). (I) RAW 264.7 CD80 expression across conditions; brackets give Welch’s t-test p-values versus immunosuppressive control. (J) MHC II within-experiment pLIFU/immunosuppressive ratio by dose (overall ratio 1.65, p = 0.0041, one-sample t-test versus 1.0). (K) CD80 normalized ratio by dose (overall 0.73, p = 0.0008). (L) MHC II dose-response regression of within-experiment ratios on peak negative pressure (R = 0.50, p = 0.059). (M) CD80 dose-response regression (R = −0.07, p = 0.81). (N) THP-1 CD80 expression across conditions (n = 2 independent experiments). (O) THP-1 ARG1 expression across conditions. (P) THP-1 HLA-DR normalized ratio by dose (overall 0.97, p = 0.64). (Q) THP-1 ARG1 normalized ratio by dose (overall 0.52, p = 0.0025). (R) THP-1 CD80 normalized ratio by dose (overall 0.64, p = 0.0006). (S) THP-1 HLA-DR expression across conditions. (T) Heat maps of mean normalized ratios for all markers across doses in RAW 264.7 (left) and THP-1 (right). (U) Forest plot of pLIFU/immunosuppressive ratios (mean and 95% confidence interval, individual ratios overlaid) for all markers in both cell lines, with the combined CD80 ratio across cell lines (diamond; 0.71, p < 0.0001, n = 21). The vertical line at 1.0 indicates no effect; values below 1.0 indicate reduced expression relative to the immunosuppressive baseline. Dashed lines at 1.0 in E, G, J, K, P, Q, and R indicate no change. All pressures are free-field peak negative pressures; measured in-well values are given in .

    Article Snippet: For immunosuppressive polarization, all wells in both cell lines were treated with 20 ng/mL recombinant human TGF-β1 (R&D Systems 7754-BH) for 24 h and left in TGF-β1 for the duration of the experiment.

    Techniques: Ex Vivo, Tissue, Incubation, In Vitro, Sample Prep, Marker, Staining, Flow Cytometry, In Vivo, Control, Expressing